TrialDrug design, development and therapy2021

Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.

Eunsol Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.